Abstract
Oncogenic osteomalacia, an acquired hypophosphataemic syndrome associated with mesenchymal tumours, is characterised by hypophosphataemia secondary to inappropriate phosphaturia, reduced concentrations of serum calcitriol, and defective bone mineralisation. Removal of these tumours results in complete reversal of these biochemical defects. However, because these tumours are small, slow-growing, and frequently situated in unusual anatomical sites, conventional imaging techniques often fail to detect them. Since mesenchymal tumours express somatostatin receptors, we postulated that somatostatin analogues would be able to detect these tumours. We did Indium-111 labeled pentetreotide imaging in seven patients with oncogenic osteomalacia. In five patients, we identified a mesenchymal tumour, and clinical improvement occurred after tumour resection. Our findings suggest that 111In-pentetreotide imaging effectively detects occult mesenchymal tumours and facilitates surgical treatment of oncogenic osteomalacia.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 761-763 |
| Number of pages | 3 |
| Journal | The Lancet |
| Volume | 359 |
| Issue number | 9308 |
| DOIs | |
| State | Published - Mar 2 2002 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Localisation of mesenchymal tumours by somatostatin receptor imaging. / Jan De Beur, Suzanne M; Streeten, Elizabeth A.; Civelek, Ali; McCarthy, Edward F; Uribe, Liliana; Marx, Stephen J.; Onobrakpeya, Olufunmilayo; Raisz, Lawrence G.; Watts, Nelson B.; Sharon, Michael; Levine, Michael A.
In: The Lancet, Vol. 359, No. 9308, 02.03.2002, p. 761-763.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Localisation of mesenchymal tumours by somatostatin receptor imaging
AU - Jan De Beur, Suzanne M
AU - Streeten, Elizabeth A.
AU - Civelek, Ali
AU - McCarthy, Edward F
AU - Uribe, Liliana
AU - Marx, Stephen J.
AU - Onobrakpeya, Olufunmilayo
AU - Raisz, Lawrence G.
AU - Watts, Nelson B.
AU - Sharon, Michael
AU - Levine, Michael A.
PY - 2002/3/2
Y1 - 2002/3/2
N2 - Oncogenic osteomalacia, an acquired hypophosphataemic syndrome associated with mesenchymal tumours, is characterised by hypophosphataemia secondary to inappropriate phosphaturia, reduced concentrations of serum calcitriol, and defective bone mineralisation. Removal of these tumours results in complete reversal of these biochemical defects. However, because these tumours are small, slow-growing, and frequently situated in unusual anatomical sites, conventional imaging techniques often fail to detect them. Since mesenchymal tumours express somatostatin receptors, we postulated that somatostatin analogues would be able to detect these tumours. We did Indium-111 labeled pentetreotide imaging in seven patients with oncogenic osteomalacia. In five patients, we identified a mesenchymal tumour, and clinical improvement occurred after tumour resection. Our findings suggest that 111In-pentetreotide imaging effectively detects occult mesenchymal tumours and facilitates surgical treatment of oncogenic osteomalacia.
AB - Oncogenic osteomalacia, an acquired hypophosphataemic syndrome associated with mesenchymal tumours, is characterised by hypophosphataemia secondary to inappropriate phosphaturia, reduced concentrations of serum calcitriol, and defective bone mineralisation. Removal of these tumours results in complete reversal of these biochemical defects. However, because these tumours are small, slow-growing, and frequently situated in unusual anatomical sites, conventional imaging techniques often fail to detect them. Since mesenchymal tumours express somatostatin receptors, we postulated that somatostatin analogues would be able to detect these tumours. We did Indium-111 labeled pentetreotide imaging in seven patients with oncogenic osteomalacia. In five patients, we identified a mesenchymal tumour, and clinical improvement occurred after tumour resection. Our findings suggest that 111In-pentetreotide imaging effectively detects occult mesenchymal tumours and facilitates surgical treatment of oncogenic osteomalacia.
UR - http://www.scopus.com/inward/record.url?scp=0037006672&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037006672&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(02)07846-7
DO - 10.1016/S0140-6736(02)07846-7
M3 - Article
C2 - 11888589
AN - SCOPUS:0037006672
VL - 359
SP - 761
EP - 763
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 9308
ER -